RS-2026-25501687

Development of a Lead Candidate for an Antigen-Presenting Cell-Based Cancer Immunotherapeutic Vaccine Targeting HPV Types 31/33/45/52/58

Cellid Co., Ltd.

CELLID
LEADER IN CELL-BASED THERAPEUTIC VACCINE

ONCOLOGY | **Lead**

Product Type	Gene & Nucleic acids
Indication	HPV 31/33/45/52/58 positive Cervical Cancer or Head and Neck Squamous Cell Carcinoma (HNSCC)
Target	HPV 31/33/45/52/58 E6, E7 protein
MoA(Mechanism of Action)	BVAC-HPVmi is an immunotherapeutic vaccine developed using the CeliVax platform, which utilizes the patient's peripheral blood mononuclear cells (PBMCs). By leveraging this platform, BVAC-HPVmi simultaneously activates innate and adaptive immune responses—specifically NK/NKT cell responses and HPV-specific $CD4^+$/$CD8^+$ T cell responses, respectively. These coordinated immune pathways elicit a potent tumor-killing effect against both antigen-positive and MHC-negative tumors 
Competitiveness	BVAC-HPVmi is a highly competitive cancer immunotherapeutic vaccine that provides a dual therapeutic effect by simultaneously inducing innate immunity through NK/NKT cells and adaptive immunity via T cells, making it particularly effective against heterogeneous cancers with mixed MHC class I expression. Beyond its biological mechanism, the CeliVax platform offers a superior manufacturing advantage with a rapid 1-day production process that significantly reduces costs and ensures timely supply compared to conventional dendritic cell, T-cell, or CAR-T therapies.  
	제조기간: 1일 / 7~14일 / 21~28일 / 21~28일 공급의 신속성: ○ / × / × / × 제조비용: 낮음 / 높음 / 매우 높음 / 매우 높음
Development Stage	Lead